Bharat Biotech International Limited Chairman Dr Krishna Ella on Monday said today's neglected infectious diseases could be tomorrow's global pandemic and stressed the need to have a coherent strategy to fight them.
He said this during an event organised as part of the 38 foundation day celebrations by CSIR-Institute of Microbial Technology (IMTECH), Chandigarh.
Bharat Biotech's Covaxin is credited to be India's first indigenous COVID-19 vaccine to be approved and administered to a sizeable population across the globe.
Delivering this year's foundation day lecture virtually on Innovation and Leadership in Pandemic, Ella highlighted how today's neglected infectious diseases could be tomorrow's global pandemic and stressed the need to have a coherent strategy to fight infectious diseases, according to an CSIR-IMTECH statement.
During his lecture, Dr Ella highlighted how innovative technology in vaccine development is essential to solve public healthcare problems caused by infectious diseases.
He said Indian pharmaceutical companies need to innovate beyond generic vaccines to be a global player in the vaccine market.
He stressed the need for scientists to examine the unknowns that could be the future cause of pandemic through zoonotic and unknown viruses.
A serial entrepreneur with a passion for innovative ideas, Bharat Biotech has also ventured into veterinary vaccines, food processing, and developing biotechnology infrastructure in the country.
Dr Ella is also involved in shaping India's science education and policy through his association with several committees, said the statement.
Dr Shekhar C Mande, Secretary, Department of Scientific and Industrial Research & Director General CSIR, asked scientists to focus on microbiome therapies, which could be future game changer for treating diseases.
Dr Sanjeev Khosla, Director, CSIR-IMTECH, lauded efforts of scientists and researchers for the work carried out to fight the pandemic during the challenging times of COVID-19.
The CSIR-IMTECH is a national centre for excellence in microbial sciences and was established in 1984.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU